Clinical Context
The decision to initiate injectable therapy in type 2 diabetes represents a critical juncture in disease management. Historically, this meant starting basal insulin when oral agents failed to maintain glycemic control. However, GLP-1 receptor agonists offer an alternative injectable option with fundamentally different characteristics: weight loss instead of weight gain, minimal hypoglycemia risk, and once-weekly dosing convenience.
The SUSTAIN 4 trial directly compared once-weekly semaglutide to once-daily insulin glargine in insulin-naive patients—addressing the clinically relevant question of which injectable to choose when oral therapy becomes insufficient. This comparison has immediate practical implications for treatment sequencing and patient counseling.
For patients and clinicians, the choice between GLP-1 RA and basal insulin involves trade-offs: insulin provides reliable glucose lowering but requires daily injection, dose titration, glucose monitoring, and often causes weight gain and hypoglycemia. GLP-1 RAs offer weight loss and reduced hypoglycemia but may cause significant gastrointestinal side effects. Understanding the magnitude of glycemic differences helps inform shared decision-making.
PICO Summary
Population: Insulin-naive adults with type 2 diabetes (n=1,089) inadequately controlled on metformin alone or with sulfonylureas.
Intervention: Once-weekly subcutaneous semaglutide at 0.5 mg or 1.0 mg for 30 weeks.
Comparison: Once-daily insulin glargine, titrated according to fasting glucose targets.
Outcome: Semaglutide 0.5 mg reduced HbA1c by 1.21% and semaglutide 1.0 mg by 1.64%, compared to 0.83% with insulin glargine. Weight decreased by 3.5-5.2 kg with semaglutide versus increased by 1.2 kg with insulin glargine. Hypoglycemia was less frequent with semaglutide. Gastrointestinal side effects (nausea, vomiting) were more common with semaglutide; injection-site reactions occurred with insulin glargine.
Clinical Pearls
1. Semaglutide Achieves Superior Glycemic Control: The 1.64% HbA1c reduction with semaglutide 1.0 mg substantially exceeds the 0.83% reduction with titrated insulin glargine. This difference (approximately 0.8% greater HbA1c lowering) translates to more patients achieving glycemic targets and reduced long-term complication risk.
2. Weight Effects Are Divergent: The ~6.5 kg weight difference between semaglutide (weight loss) and insulin glargine (weight gain) over 30 weeks is clinically meaningful. For patients concerned about weight—which includes most patients with type 2 diabetes—this difference often determines treatment preference.
3. Hypoglycemia Reduction Despite Better Control: Semaglutide achieved lower HbA1c with less hypoglycemia—a combination not typically possible with insulin. This reflects GLP-1 RA’s glucose-dependent mechanism: enhanced insulin secretion when glucose is high, but not when glucose is normal or low.
4. Once-Weekly vs Once-Daily Administration: Beyond efficacy differences, semaglutide’s once-weekly dosing reduces injection burden compared to daily insulin. For patients hesitant about injectables, weekly dosing may improve acceptance and adherence.
Practical Application
When patients with type 2 diabetes require injectable therapy escalation, GLP-1 RAs like semaglutide should generally be preferred over basal insulin as the first injectable for most patients. The superior glycemic efficacy, weight benefits, and reduced hypoglycemia favor GLP-1 RAs in the absence of specific contraindications.
Reserve basal insulin as the first injectable when: severe hyperglycemia suggests significant insulin deficiency (HbA1c >10-11%, symptomatic hyperglycemia), cost/access barriers preclude GLP-1 RA use, or GLP-1 RA intolerance prevents adequate dosing. Some patients may require both agents eventually.
When discussing options with patients, frame the choice honestly: semaglutide offers better glucose control with weight loss but may cause nausea initially; insulin provides reliable glucose lowering but often causes weight gain and requires more monitoring. Most patients, when informed, prefer the GLP-1 RA option.
Broader Evidence Context
SUSTAIN 4 is one of several trials comparing GLP-1 RAs to basal insulin. Similar results have been demonstrated with other GLP-1 RAs (liraglutide, dulaglutide, exenatide). Current guidelines (ADA, EASD) now recommend GLP-1 RAs before or instead of basal insulin for most patients requiring injectable therapy intensification, representing a paradigm shift from traditional insulin-first approaches.
The cardiovascular outcome trial SUSTAIN-6 subsequently demonstrated that semaglutide reduces cardiovascular events—a benefit not definitively established for basal insulin. This adds another dimension favoring GLP-1 RAs in patients with cardiovascular disease or risk factors.
Study Limitations
The open-label design may have influenced patient-reported outcomes and treatment discontinuation decisions. The 30-week duration establishes short-term superiority but doesn’t capture long-term durability. Insulin glargine dosing may not have been optimized to maximum potential in all patients. The population excluded patients requiring higher insulin doses, limiting generalizability to advanced insulin deficiency.
Bottom Line
Once-weekly semaglutide provides superior glycemic control compared to daily insulin glargine in insulin-naive patients with type 2 diabetes, with the added benefits of weight loss and reduced hypoglycemia. These findings support GLP-1 RAs as the preferred first injectable therapy for most patients requiring treatment intensification beyond oral agents.
Source: Aroda VR, et al. “Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin (With or Without Sulfonylureas) in Insulin-Naive Patients with Type 2 Diabetes (SUSTAIN 4): A Randomised, Open-Label, Parallel-Group, Multicentre, Multinational, Phase 3a Trial.” Lancet Diabetes & Endocrinology, 2017;5(5):355-366. Read article
